HIPEC for colorectal peritoneal metastases

Affiliations

¹ Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA, USA.
² Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA, USA. Electronic address: dpryan@mgh.harvard.edu.

Comment

Samuel J Klempner et al. Lancet Oncol. 2021 Feb.

. 2021 Feb;22(2):162-164.

doi: 10.1016/S1470-2045(20)30693-8. Epub 2021 Jan 18.

¹ Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA, USA.
² Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA, USA. Electronic address: dpryan@mgh.harvard.edu.

No abstract available

Comment on

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O; UNICANCER-GI Group and BIG Renape Group. Quénet F, et al. Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476595 Clinical Trial.